# DESCRIPTION

- claim priority benefit

## FIELD OF THE INVENTION

- relate to bone growth velocity measurement

## BACKGROUND OF THE INVENTION

- introduce growth as integral component of human development
- describe skeletal growth measurement
- discuss growth disorders and diseases
- summarize publications on skeletal bone growth
- describe limitations of stadiometer-based height velocity determination
- discuss reliability of height measurement
- introduce need for accurate bone growth velocity measurement
- summarize prior art

## SUMMARY OF THE INVENTION

- introduce method for determining bone growth velocity
- describe measurement of CXM using aptamer and antibody
- outline solid phase binding assay
- describe multiplex assay
- introduce preferred reagents SOMA1 and mAb X34
- describe quantification of CXM in sample
- outline method for determining bone growth velocity
- describe applications of CXM measurement
- introduce methods for treating diseases and disorders
- describe embodiments of sample and assay

## DETAILED DESCRIPTION OF THE INVENTION

- introduce patent application
- define technical and scientific terms
- define CXM and Cxm
- define bone growth velocity
- define mAb
- define binding reagent
- define reporter molecule
- define subject
- define sample
- describe method for determining bone growth velocity
- describe capture reagent
- describe detection reagent
- describe ELISA method
- describe multiplex assay format
- describe aptamer capture reagent
- describe antibody capture reagent
- describe aptamer detection reagent
- describe antibody detection reagent
- describe conjugation of detection reagent to reporter molecule
- describe quantification of collagen X marker
- describe generation of standard curve
- describe method for measuring CXM to monitor bone growth response
- describe measuring CXM to monitor intervention or treatment
- describe measuring CXM to identify pubertal growth spurt
- describe measuring CXM to monitor bone fracture healing
- describe measuring CXM to monitor or detect osteoarthritis
- describe measuring CXM to monitor or detect cancer
- describe measuring CXM to monitor or detect heterotopic ossification
- describe measuring CXM to monitor or detect other diseases or disorders
- describe purified collagen X marker
- describe purification process using aptamer
- describe purification process using antibody
- describe purification process using aptamer and antibody
- describe level of purity for purified collagen X marker
- introduce examples
- describe sample collection and processing
- describe recombinant proteins and antibodies

### Examples

- describe sample collection and processing
- describe height and weight measurements
- describe growth velocity calculation
- describe diurnal variation testing
- describe fracture healing sample collection
- describe DBS sample collection and storage
- describe CXM concentration testing

### Recombinant Proteins

- describe recombinant proteins to human and mouse NC1 regions

### Type X Collagen Antibodies

- describe type X collagen antibodies

### Components for ELISAs

- list ELISA plate and reagents
- define ELISA buffers
- list other buffers and components

### Identification of Marker in “Depleted” Cord Serum

- describe serum depletion and Western blot procedure

### Immunoprecipitation, Aptoprecipitation and Western Blot Procedures

- describe immunoprecipitation and aptoprecipitation procedures
- describe Western blot procedure

### Purification of Marker

- describe cord plasma preparation and SOMA1-magnetic beads binding
- describe washing and elution of CXM

### Mass Spectrometry

- describe CXM purification and concentration
- describe SDS-PAGE and Western blot analysis
- describe mass spectrometry analysis and data processing

### Development of SOMAmer Capture Reagent for CXM

- develop recombinant human NC1 region
- biotinylate and submit for SELEX affinity capture
- pre-adsorb proteins to avoid cross reactivity
- generate high affinity SOMAmers
- select SOMA1 due to high affinity and low steric hindrance
- describe assay procedure
- prepare sample incubations
- perform detector and reporter incubations
- develop and read ELISA assay
- prepare ELISA assay calibrators and controls
- describe DBS elution procedure
- compare growth velocity to CXM levels in mouse
- perform half-life and stability testing
- introduce CXM ELISA for freeze/thaw analysis
- perform temperature stability analysis
- perform DBS stability analysis
- summarize statistical analysis
- plot CXM concentration against age
- generate scatterplots and linear fit summary lines
- calculate Pearson's correlation and statistical significance
- generate power series fitted summary line
- describe lower limit of quantitation calculations
- perform lower limit of blank and lower limit of quantitation testing
- describe type X collagen structure
- perform SDS-PAGE/western blot analysis
- immunoprecipitate CXM eluted at pH 7.0 versus pH 2.5
- perform mass spectrometry of purified/trypsinized marker
- identify high-confidence peptides
- describe functional domains
- perform aptoprecipitation using SOMAmer
- analyze CXM abundance by age and sample source
- perform western blot analysis of aptoprecipitates
- compare serum and urine samples from a single 2 month old infant
- analyze marker in mice age 1-12 weeks
- plot Cxm serum concentration against age and growth velocities
- correlate Cxm concentrations with femur and tibia growth velocities
- develop human CXM ELISA assay
- summarize performance characteristics of marker assay
- plot lower limit of quantitation for CXM
- analyze marker in healthy infants and children
- plot serum CXM against age for normally growing infants and children
- correlate CXM with height velocity
- plot log-transformed CXM serum concentrations against age
- compare CXM concentrations between males and females
- superimpose established growth velocity curves
- document CXM concentrations parallel growth velocity standards
- introduce human growth velocity measurements
- plot CXM concentration against annualized height velocity
- document normal growth in study population
- compare CXM-based estimates to stadiometer-based height velocity
- introduce CXM in healthy adults
- describe CXM in adult fracture healing
- compare serum, plasma, and DBS samples
- assess biologic variation of CXM
- determine CXM half-life
- summarize CXM as a marker for linear skeletal growth velocity
- introduce CXM identification, characterization, and assay
- describe type X collagen synthesis and degradation
- discuss collagenase cleavage sites
- analyze mouse Cxm and human CXM
- discuss CXM stability in vitro
- compare CXM concentrations across sample types
- discuss clinical relevance of CXM
- relate CXM to established human growth data
- compare CXM to average growth velocity
- discuss correlation of CXM to growth velocity
- introduce CXM-based estimates of height velocity
- compare CXM to stadiometer-based height velocity
- discuss utility of CXM in monitoring growth response
- describe potential applications of CXM
- discuss diurnal variation of CXM
- relate CXM to bone growth and conventional parameters
- discuss potential applications beyond bone growth
- introduce CXM in idiopathic scoliosis management
- discuss CXM in fracture healing
- relate CXM to osteoarthritis activity
- discuss type X collagen in cancer detection
- summarize CXM as a real-time indicator of skeletal growth velocity
- discuss CXM as a tool for investigating short-term variations
- relate CXM to linear bone growth
- discuss potential applications of CXM in resource-restricted regions
- introduce CXM in monitoring growth response to interventions
- discuss CXM in assessing and comparing therapeutic interventions
- relate CXM to growth hormone and C-type natriuretic peptide derivative therapies
- discuss CXM in programmatic interventions for malnutrition and chronic diseases
- introduce CXM in investigating endochondral ossification
- discuss CXM in articular chondrocyte terminal differentiation
- relate CXM to type X collagen in cancer detection
- discuss CXM as a marker for cancer detection in adults
- summarize CXM as a degradation by-product of skeletal growth
- conclude CXM as a real-time marker for linear skeletal growth velocity

